Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Index by author

January 01, 1986; Volume 29,Issue 1
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

B

  1. Bali, J P

    1. You have access
      Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets.
      R Magous, J P Bali, R Escale, J P Girard, E Rechencq and J C Rossi
      Molecular Pharmacology January 1986, 29 (1) 39-44;
  2. Black, K A

    1. You have access
      Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins.
      T R Tephly, K A Black, M D Green, B L Coffman, G A Dannan and F P Guengerich
      Molecular Pharmacology January 1986, 29 (1) 81-87;
  3. Bocckino, S B

    1. You have access
      Regulation of protein synthesis in isolated hepatocytes by calcium-mobilizing hormones.
      C O Brostrom, S B Bocckino, M A Brostrom and E M Galuska
      Molecular Pharmacology January 1986, 29 (1) 104-111;
  4. Britt, M

    1. You have access
      The interaction of the beta-anomer of doxorubicin with B and Z DNA.
      M Britt, F Zunino and J B Chaires
      Molecular Pharmacology January 1986, 29 (1) 74-80;
  5. Brostrom, C O

    1. You have access
      Regulation of protein synthesis in isolated hepatocytes by calcium-mobilizing hormones.
      C O Brostrom, S B Bocckino, M A Brostrom and E M Galuska
      Molecular Pharmacology January 1986, 29 (1) 104-111;
  6. Brostrom, M A

    1. You have access
      Regulation of protein synthesis in isolated hepatocytes by calcium-mobilizing hormones.
      C O Brostrom, S B Bocckino, M A Brostrom and E M Galuska
      Molecular Pharmacology January 1986, 29 (1) 104-111;

C

  1. Cascieri, M A

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;
  2. Chaires, J B

    1. You have access
      The interaction of the beta-anomer of doxorubicin with B and Z DNA.
      M Britt, F Zunino and J B Chaires
      Molecular Pharmacology January 1986, 29 (1) 74-80;
  3. Chicchi, G G

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;
  4. Coffman, B L

    1. You have access
      Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins.
      T R Tephly, K A Black, M D Green, B L Coffman, G A Dannan and F P Guengerich
      Molecular Pharmacology January 1986, 29 (1) 81-87;
  5. Colton, C D

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;
  6. Couvineau, A

    1. You have access
      Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
      M Laburthe, A Couvineau and C Rouyer-Fessard
      Molecular Pharmacology January 1986, 29 (1) 23-27;
  7. Curtis, N R

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;

D

  1. Dannan, G A

    1. You have access
      Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins.
      T R Tephly, K A Black, M D Green, B L Coffman, G A Dannan and F P Guengerich
      Molecular Pharmacology January 1986, 29 (1) 81-87;
  2. Dempster, J

    1. You have access
      The effects of chloramphenicol isomers on the motor end-plate nicotinic receptor-ion channel complex.
      F Henderson, C Prior, J Dempster and I G Marshall
      Molecular Pharmacology January 1986, 29 (1) 52-64;

E

  1. Escale, R

    1. You have access
      Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets.
      R Magous, J P Bali, R Escale, J P Girard, E Rechencq and J C Rossi
      Molecular Pharmacology January 1986, 29 (1) 39-44;

F

  1. Ferry, N

    1. You have access
      Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
      H J Motulsky, S J Shattil, N Ferry, D Rozansky and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 1-6;
  2. Foxall, D

    1. You have access
      Nuclear magnetic resonance studies of carbohydrate metabolism and substrate cycling in Fasciola hepatica.
      P M Matthews, D Foxall, L Shen and T E Mansour
      Molecular Pharmacology January 1986, 29 (1) 65-73;
  3. Freidinger, R M

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;

G

  1. Galuska, E M

    1. You have access
      Regulation of protein synthesis in isolated hepatocytes by calcium-mobilizing hormones.
      C O Brostrom, S B Bocckino, M A Brostrom and E M Galuska
      Molecular Pharmacology January 1986, 29 (1) 104-111;
  2. Girard, J P

    1. You have access
      Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets.
      R Magous, J P Bali, R Escale, J P Girard, E Rechencq and J C Rossi
      Molecular Pharmacology January 1986, 29 (1) 39-44;
  3. Green, M D

    1. You have access
      Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins.
      T R Tephly, K A Black, M D Green, B L Coffman, G A Dannan and F P Guengerich
      Molecular Pharmacology January 1986, 29 (1) 81-87;
  4. Guengerich, F P

    1. You have access
      Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins.
      T R Tephly, K A Black, M D Green, B L Coffman, G A Dannan and F P Guengerich
      Molecular Pharmacology January 1986, 29 (1) 81-87;

H

  1. Harris, C

    1. You have access
      A new method to study glutathione adduct formation in periportal and pericentral regions of the liver lobule by micro-reflectance spectrophotometry.
      C Harris and R G Thurman
      Molecular Pharmacology January 1986, 29 (1) 88-96;
  2. Henderson, F

    1. You have access
      The effects of chloramphenicol isomers on the motor end-plate nicotinic receptor-ion channel complex.
      F Henderson, C Prior, J Dempster and I G Marshall
      Molecular Pharmacology January 1986, 29 (1) 52-64;

I

  1. Insel, P A

    1. You have access
      Expression of beta-adrenergic receptors in synchronous and asynchronous S49 lymphoma cells. II. Relationship between receptor number and response.
      L C Mahan and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 16-22;
    2. You have access
      Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
      H J Motulsky, S J Shattil, N Ferry, D Rozansky and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 1-6;
    3. You have access
      Expression of beta-adrenergic receptors in synchronous and asynchronous S49 lymphoma cells. I. Receptor metabolism after irreversible blockade of receptors and in cells traversing the cell division cycle.
      L C Mahan and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 7-15;

J

  1. Johnson, G V

    1. You have access
      Quinacrine and 2-(4-phenylpiperidino)cyclohexanol (AH5183) inhibit acetylcholine release and synthesis in rat brain slices.
      R S Jope and G V Johnson
      Molecular Pharmacology January 1986, 29 (1) 45-51;
  2. Jope, R S

    1. You have access
      Quinacrine and 2-(4-phenylpiperidino)cyclohexanol (AH5183) inhibit acetylcholine release and synthesis in rat brain slices.
      R S Jope and G V Johnson
      Molecular Pharmacology January 1986, 29 (1) 45-51;

L

  1. Laburthe, M

    1. You have access
      Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
      M Laburthe, A Couvineau and C Rouyer-Fessard
      Molecular Pharmacology January 1986, 29 (1) 23-27;
  2. Larsen, G L

    1. You have access
      Cysteine conjugate beta-lyase in the gastrointestinal bacterium Eubacterium limosum.
      G L Larsen and J L Stevens
      Molecular Pharmacology January 1986, 29 (1) 97-103;

M

  1. Magous, R

    1. You have access
      Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets.
      R Magous, J P Bali, R Escale, J P Girard, E Rechencq and J C Rossi
      Molecular Pharmacology January 1986, 29 (1) 39-44;
  2. Maguire, J J

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;
  3. Mahan, L C

    1. You have access
      Expression of beta-adrenergic receptors in synchronous and asynchronous S49 lymphoma cells. II. Relationship between receptor number and response.
      L C Mahan and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 16-22;
    2. You have access
      Expression of beta-adrenergic receptors in synchronous and asynchronous S49 lymphoma cells. I. Receptor metabolism after irreversible blockade of receptors and in cells traversing the cell division cycle.
      L C Mahan and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 7-15;
  4. Mansour, T E

    1. You have access
      Nuclear magnetic resonance studies of carbohydrate metabolism and substrate cycling in Fasciola hepatica.
      P M Matthews, D Foxall, L Shen and T E Mansour
      Molecular Pharmacology January 1986, 29 (1) 65-73;
  5. Marshall, I G

    1. You have access
      The effects of chloramphenicol isomers on the motor end-plate nicotinic receptor-ion channel complex.
      F Henderson, C Prior, J Dempster and I G Marshall
      Molecular Pharmacology January 1986, 29 (1) 52-64;
  6. Matthews, P M

    1. You have access
      Nuclear magnetic resonance studies of carbohydrate metabolism and substrate cycling in Fasciola hepatica.
      P M Matthews, D Foxall, L Shen and T E Mansour
      Molecular Pharmacology January 1986, 29 (1) 65-73;
  7. Mazurek, A P

    1. You have access
      Theoretical studies on the activation mechanism of the histamine H2-receptor: the proton transfer between histamine and a receptor model.
      H Weinstein, A P Mazurek, R Osman and S Topiol
      Molecular Pharmacology January 1986, 29 (1) 28-33;
  8. McKnight, A T

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;
  9. Motulsky, H J

    1. You have access
      Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
      H J Motulsky, S J Shattil, N Ferry, D Rozansky and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 1-6;

O

  1. Osman, R

    1. You have access
      Theoretical studies on the activation mechanism of the histamine H2-receptor: the proton transfer between histamine and a receptor model.
      H Weinstein, A P Mazurek, R Osman and S Topiol
      Molecular Pharmacology January 1986, 29 (1) 28-33;

P

  1. Perlow, D S

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;
  2. Prior, C

    1. You have access
      The effects of chloramphenicol isomers on the motor end-plate nicotinic receptor-ion channel complex.
      F Henderson, C Prior, J Dempster and I G Marshall
      Molecular Pharmacology January 1986, 29 (1) 52-64;

R

  1. Rechencq, E

    1. You have access
      Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets.
      R Magous, J P Bali, R Escale, J P Girard, E Rechencq and J C Rossi
      Molecular Pharmacology January 1986, 29 (1) 39-44;
  2. Rossi, J C

    1. You have access
      Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets.
      R Magous, J P Bali, R Escale, J P Girard, E Rechencq and J C Rossi
      Molecular Pharmacology January 1986, 29 (1) 39-44;
  3. Rouyer-Fessard, C

    1. You have access
      Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
      M Laburthe, A Couvineau and C Rouyer-Fessard
      Molecular Pharmacology January 1986, 29 (1) 23-27;
  4. Rozansky, D

    1. You have access
      Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
      H J Motulsky, S J Shattil, N Ferry, D Rozansky and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 1-6;

S

  1. Shattil, S J

    1. You have access
      Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
      H J Motulsky, S J Shattil, N Ferry, D Rozansky and P A Insel
      Molecular Pharmacology January 1986, 29 (1) 1-6;
  2. Shen, L

    1. You have access
      Nuclear magnetic resonance studies of carbohydrate metabolism and substrate cycling in Fasciola hepatica.
      P M Matthews, D Foxall, L Shen and T E Mansour
      Molecular Pharmacology January 1986, 29 (1) 65-73;
  3. Stevens, J L

    1. You have access
      Cysteine conjugate beta-lyase in the gastrointestinal bacterium Eubacterium limosum.
      G L Larsen and J L Stevens
      Molecular Pharmacology January 1986, 29 (1) 97-103;

T

  1. Tephly, T R

    1. You have access
      Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins.
      T R Tephly, K A Black, M D Green, B L Coffman, G A Dannan and F P Guengerich
      Molecular Pharmacology January 1986, 29 (1) 81-87;
  2. Thurman, R G

    1. You have access
      A new method to study glutathione adduct formation in periportal and pericentral regions of the liver lobule by micro-reflectance spectrophotometry.
      C Harris and R G Thurman
      Molecular Pharmacology January 1986, 29 (1) 88-96;
  3. Topiol, S

    1. You have access
      Theoretical studies on the activation mechanism of the histamine H2-receptor: the proton transfer between histamine and a receptor model.
      H Weinstein, A P Mazurek, R Osman and S Topiol
      Molecular Pharmacology January 1986, 29 (1) 28-33;

V

  1. Veber, D F

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;

W

  1. Weinstein, H

    1. You have access
      Theoretical studies on the activation mechanism of the histamine H2-receptor: the proton transfer between histamine and a receptor model.
      H Weinstein, A P Mazurek, R Osman and S Topiol
      Molecular Pharmacology January 1986, 29 (1) 28-33;
  2. Williams, B

    1. You have access
      Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.
      M A Cascieri, G G Chicchi, R M Freidinger, C D Colton, D S Perlow, B Williams, N R Curtis, A T McKnight, J J Maguire and D F Veber
      Molecular Pharmacology January 1986, 29 (1) 34-38;

Z

  1. Zunino, F

    1. You have access
      The interaction of the beta-anomer of doxorubicin with B and Z DNA.
      M Britt, F Zunino and J B Chaires
      Molecular Pharmacology January 1986, 29 (1) 74-80;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 29, Issue 1
1 Jan 1986
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics